Mandatory FDA Review Of Pivotal Trial Protocols Urged In JAMA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Dartmouth researchers say that although FDA recommendations can strengthen study designs and improve outcome measures, sponsors often don’t follow agency’s advice or don’t even seek input in Phase III design.